CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zymeworks Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zymeworks Inc
114 East 4th Avenue, Suite 800
Phone: (302) 274-8744p:302 274-8744 VANCOUVER, BC  V5T 1G4  Canada Ticker: ZYMEZYME
Business Summary
Zymeworks Inc. is a global biotechnology company building a diversified portfolio of healthcare assets. The Company's asset and royalty aggregation strategy combines a portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. The Company's portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by it and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using the Company's proprietary antibody engineering technologies. The Company is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its product candidates include ZW191, ZW251, ZW220, ZW209 and ZW1528.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Kenneth H.Galbraith 63 4/1/2026 1/1/2022
Chief Financial Officer, Executive Vice President KristinStafford 44 4/1/2026 4/1/2026
Chief Operating Officer, Executive Vice President MarkHollywood 56 1/9/2026 1/9/2026
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Theravance Biopharma Ireland Limited Connaught House 1, Burlington Road Dublin Ireland
Zymeworks BC Inc 114 East 4th Avenue, Suite 800 VANCOUVER BC Canada
Theravance Biopharma US, Inc. 901 Gateway Blvd San Francisco CA United States
Theravance Biopharma R&D, Inc. 901 Gateway Boulevard San Francisco CA United States
Theravance Biopharma Inc c/o Theravance Biopharma US SOUTH SAN FRANCISCO CA United States

Business Names
Business Name
Kairos Therapeutics
Theravance Biopharma Inc
Theravance Biopharma Ireland Limited
12 additional Business Names available in full report.

General Information
Number of Employees: 231 (As of 6/30/2026)
Outstanding Shares: 71,509,241 (As of 8/4/2026)
Shareholders: 72
Stock Exchange: NASD
Fax Number: (206) 237-0892


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, October 4, 2026